Wanbury Ltd has reported standalone net sales of Rs 388.47 crore for the 18 months period ended September 2008 and its standalone net profit touched to Rs. 29.78 crore. Earnings per share (EPS) for 18 months period worked out to Rs 20.55. On an annual basis its net sales increased by 77.4 per cent. However, its net profit on annual basis declined by 4.7 per cent. The company's consolidated net sales amounted to Rs 618.49 crore and its consolidated net profit stood at Rs 31.54 crore.

At operational level the company has improved margins by approx. 3.91 per cent mainly due to reduced cost of goods sold as a percentage of sales. The company however has provided for forex losses (provision) mainly on account of FCCBs which are unlikely to materialize. This provision has brought down the margins by 3 per cent. The net margins reduced on account of lower other income in the current period and forex gains which were there in the previous period. There is also a reduction in net margin on account of higher interest and depreciation. In the previous period there was recognition of Deferred Tax Asset which resulted in a higher PAT margin by 4 per cent.

The company has moved up 38 ranks from 86th Rank to 48th Rank as per ORG IMS and its four brands are amongst the "top 3 brands" in their respective segments - viz. CPink, Folinine, Rabiplus and Adtrol. The company launched successful new brand in value added branded generics - Cdense and Nitrofur-SR.

The company has fast growing presence in CRAMS catering to large MNCs globally for manufacturing their products. Wanbury has its sales office in Zurich, Switzerland and caters to US and European markets through its US FDA plants. The company exports to over 70 countries, 65 per cent of which is to the regulated markets. Wanbury has two US FDA approved multi-product API facilities for regulated markets. The company has filed over 27 DMFs (Drug Master Files). Wanbury has pan India presence in ethical formulations with a portfolio of 52 brands.

Wanbury has presence in branded ethical finished dosage forms in Spain through Cantabria Pharma S.L., its subsidiary. Cantabria Pharma S.L., head quartered at Madrid, Spain, which employs over 100 people caters to key therapeutic areas like psychiatry, CNS, CVS, respiratory and pain management.